FCG.AX Freedom Care Group spike to 1.18M volume 10 Feb 2026: watch price

A heavy intraday trade pushed FCG.AX stock volume to 1,184,838 shares on 10 Feb 2026 while the price sits at A$0.037. The spike lifted intraday range to a high of A$0.059 from an open at A$0.059, with average daily volume at 30,060, signalling a liquidity event rather than steady demand. We flag this because the healthcare peer group trades at a much higher average PE, and sudden flows can reprice small caps quickly. Meyka AI-powered market analysis platform flags the move for traders watching short-term volatility and possible trend confirmation.

Intraday volume spike in FCG.AX stock

Today’s volume of 1,184,838 is about 39.42x the stock’s average of 30,060, a clear volume spike during ASX intraday trading. That surge compressed prices between the day low A$0.037 and day high A$0.059, indicating active buying and selling around a very small market cap of A$4,007,738.

What the raw numbers show for FCG.AX stock

Key fundamentals are mixed: reported EPS is 0.01, and the trailing PE is about 4.50, well below the Healthcare sector average PE of 32.54. The 50-day average price is A$0.037 and the 200-day average is A$0.113, showing a long-term downtrend with short-term price support at current levels.

Valuation, liquidity and sector context

FCG.AX operates in Healthcare (Medical – Care Facilities) with a price-to-sales ratio of 0.21 and a price-to-book of 0.75, suggesting low valuation relative to peers. The company’s current ratio is 2.12, and debt-to-equity is 0.46, which supports short-term solvency despite operating margin weakness reported in metrics.

Catalysts, risks and trading drivers

Catalysts that could sustain the volume spike include NDIS contract updates, earnings surprises, or M&A interest. Main risks are low market cap, limited free float, and volatile intraday swings; a small block trade or news item can move the stock sharply. Traders should watch upcoming corporate updates and NDIS sector headlines.

Meyka AI rates FCG.AX with a score out of 100

Meyka AI rates FCG.AX with a score out of 100: 69.77 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are model outputs and are not guarantees or tailored advice.

Trading note and short-term technicals

Intraday action shows high relative volume and wide spreads, so short-term traders should size positions to risk. The stock’s 50-day average at A$0.037 acts as immediate support and a break below could prompt quick downside. Compare live flows and order book depth on tools like the Investing.com ASX comparison page and check the FCG.AX page on Meyka.

Final Thoughts

The intraday volume spike to 1,184,838 shares on 10 Feb 2026 makes FCG.AX stock a short-term liquidity story in the ASX small-cap healthcare space. Fundamentals show a low trailing PE near 4.50, modest cash per share of A$0.038, and a current ratio of 2.12, which together suggest solvency but no guarantee of recovery. Meyka AI’s forecast model projects a 12-month base case target of A$0.085, implying an upside of 129.73% versus the current A$0.037. A downside scenario to A$0.020 implies a potential fall of -45.95%. Forecasts are model-based projections and not guarantees. Given the high intraday volume and small market cap, investors should treat FCG.AX as higher risk, size positions carefully, and monitor NDIS sector news and company updates for confirmation before increasing exposure.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.